EGFR and non-small cell lung carcinoma: In addition, the expression levels of DNA-PKcs and phospho-DNA-PKcs were significantly repressed when a combination of RUNX3 re-expression and 47Sc-DTPA-cetuximab was applied (Fig. 6B); this results suggests that RUNX3 acts as a major factor in the process of DNA damage and repair induced by cetuximab and the ionizing radiation emitting therapeutic radioisotope 47Sc, at least in these EGFR-overexpressing NSCLC cells.